Clinical Trials Logo

Atrial Fibrillation clinical trials

View clinical trials related to Atrial Fibrillation.

Filter by:

NCT ID: NCT02022020 Completed - Atrial Fibrillation Clinical Trials

Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

Start date: January 2014
Phase: N/A
Study type: Observational

This study is being conducted to collect data on the management of gastrointestinal and urogenital bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.

NCT ID: NCT02019407 Completed - Atrial Fibrillation Clinical Trials

Prospective Randomized Study on Clinical Effectiveness of Carvo-Tricuspid Isthmus Block in Patients With Paroxysmal Atrial Fibrillation

Start date: January 2015
Phase: N/A
Study type: Interventional

Prospective Randomized Study on Clinical Effectiveness of Carvo-Tricuspid Isthmus (CTI) Block in Patients with Paroxysmal Atrial Fibrillation (PAF) will be performed. Study will be composed with two arms including 4 pulmonary vein isolation and pulmonary vein isolation with CTI block. After that all patients will be followed up by HRS(Heart Rhythm Society) 2010 expert consensus guideline.

NCT ID: NCT02017197 Completed - Atrial Fibrillation Clinical Trials

Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil

WARFA
Start date: August 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.

NCT ID: NCT02016950 Completed - Atrial Fibrillation Clinical Trials

Long-term Pacemaker Arrhythmia Analysis

Start date: June 2014
Phase: N/A
Study type: Observational

Investigators seek to observe the long term patterns of arrhythmias detected by permanent pacemakers.

NCT ID: NCT02014896 Completed - Atrial Fibrillation Clinical Trials

Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

BASE
Start date: December 2013
Phase:
Study type: Observational

The proposed study will validate the clinical use of new biomarker blood tests to identify blood components that may differentiate between diverse stroke etiologies and clinical outcomes as listed below: 1. Differentiate between cardioembolic and large artery atherosclerotic ischemic strokes, when hemorrhagic stroke is ruled out. 2. In cases of ischemic strokes of unknown or "cryptogenic" etiology, determine the ability of biomarker blood tests to predict etiology between cardioembolic and large artery atherosclerotic. 3. In cases of cardioembolic ischemic stroke, further differentiation of cardioembolic ischemic strokes into those caused by atrial fibrillation (AF) and those not caused by AF. 4. Differentiate "transient ischemic attacks" (TIAs) from acute ischemic strokes. 5. Differentiate TIAs from non-ischemic "transient neurological events" (TNE) with similar symptoms.

NCT ID: NCT02011256 Completed - Atrial Fibrillation Clinical Trials

Early Detection Of Atrial Fibrillation In Patients With Transient Ischemic Attack

NOTICE
Start date: September 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the frequency of atrial fibrillation in patients with transient ischemic attack (TIA). Patients suffering TIA will have their heart rhythm extensively monitored with 72-hour Holter-monitoring and an implantable loop-recorder. Furthermore, the patients will be examined with echocardiography, coronary calcium-score and biomarkers with the purpose to predict which subjects at risk for developing atrial fibrillation.

NCT ID: NCT02008747 Completed - Atrial Fibrillation Clinical Trials

Atrial Fibrillation and Neuropathic Pain After Thoracotomy and Continuous Application of Magnesium Sulphate.

Start date: January 2011
Phase: N/A
Study type: Interventional

Atrial fibrillation and chronic neuropathic pain are adverse events occurring after posterolateral thoracotomy for lung resection. The continuous application of magnesium sulphate may have a prophylactic effect. The investigators record the incidence of atrial fibrillation during a seven day period after thoracotomy as well as the incidence of chronic neuropathic pain during a three months period, comparing one group with a continuous application of magnesium sulphate against one group without magnesium sulphate.

NCT ID: NCT02007655 Completed - Clinical trials for NonValvular Atrial Fibrillation

Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation

Start date: September 1, 2013
Phase:
Study type: Observational

The primary objectives of this study are: - To estimate the incidence rate of unexpected adverse events - To characterize the bleeding events and assess risk factors of bleeding - To identify ancillary baseline variables that may also be associated with adverse outcomes

NCT ID: NCT02006524 Completed - Atrial Fibrillation Clinical Trials

Screening for Silent Atrial Fibrillation During Influenza Vaccination

Start date: October 2013
Phase: N/A
Study type: Interventional

Silent atrial fibrillation is an important cause of unnecessary strokes. If diagnosed and treated in time with anticoagulants, many disabling strokes can be prevented. In order to improve the diagnosis of atrial fibrillation the MyDiagnostick is developed; a user friendly and easy to use stick that diagnoses atrial fibrillation in one minute. During influenza vaccination, many patients who are also at risk for atrial fibrillation visit the general practice. This offers an ideal opportunity for screening for atrial fibrillation. The study investigates the yield of screening for atrial fibrillation with the MyDiagnostick during influenza vaccination (newly detected atrial fibrillation with corresponding CHA2DS2-Vasc score).

NCT ID: NCT01999829 Completed - Atrial Fibrillation Clinical Trials

Prevention of Atrial Fibrillation Following Valvular Replacement With Cardiopulmonary Bypass: a Prospective, Randomized Clinical Study Comparing Oral Caffeine With Placebo

Start date: October 2013
Phase: Phase 3
Study type: Interventional

Atrial fibrillation remains a major cause of morbidity following cardiac surgery with cardiopulmonary bypass. Many mechanisms have been implicated. Among then, adenosine, a strong endogenous vasodilating agent has been involved in cardiac surgery-induced atrial fibrillation, via A2A receptors modulation. The effects of caffeine on the inducibility of atrial fibrillation are actually well-known, leading then to a significant reduction of atrial fibrillation. Moreover, a recent clinical study has demonstrated that coffee drinking was inversely associated with total and cause-specific mortality. The investigators therefore examined the preventive effects of oral caffeine on valvular surgery with cardiopulmonary bypass-induced atrial fibrillation. The investigators also evaluated prospectively the influence of caffeine on adenosine plasma levels and A2A adenosine receptors modulation.